Akeagen’s proprietary CaMouseTM/CanAbsTM platform (patent pending) combines the full diversity of mouse immune system with powerful antibody engineering technologies to generate monoclonal single domain antibody-based drug candidates against novel and complex targets with great efficacy.

Properties of CanAbsTM monoclonal single domain antibodies:

• High affinity, stability and specificity due to in vivo maturation

• useful for challenging targets

• Unique binding capacity to hidden epitopes (small cavities or clefts)

• single domain offering fast-track lead optimization

• Easy to engineer bi-specific and tri-specific antibodies

• Highly stable under extreme temperature and pH

• Enhanced tissue penetration, cross blood-brain-barrier

• Humanization much easier than conventional monoclonal antibodies

• Cost-effective large-scale production